A5019066502- Gastric Cancer Management and Outcomes
- Chronic Lymphocytic Leukemia Research
- Colorectal Cancer Treatments and Studies
- Lymphoma Diagnosis and Treatment
- Economic and Financial Impacts of Cancer
- Acute Lymphoblastic Leukemia research
- Health Systems, Economic Evaluations, Quality of Life
- CAR-T cell therapy research
- Lung Cancer Treatments and Mutations
- Esophageal Cancer Research and Treatment
- Migraine and Headache Studies
- Radiomics and Machine Learning in Medical Imaging
- Metastasis and carcinoma case studies
- Multiple and Secondary Primary Cancers
- Psychosomatic Disorders and Their Treatments
- Erythropoietin and Anemia Treatment
- Mental Health and Psychiatry
- Hemoglobinopathies and Related Disorders
- Trigeminal Neuralgia and Treatments
- Genetic factors in colorectal cancer
- Mental Health Research Topics
- Chronic Myeloid Leukemia Treatments
- Cancer Genomics and Diagnostics
- Schizophrenia research and treatment
- Renal and related cancers
Bristol-Myers Squibb (United States)
2017-2019
Amgen (United States)
2012-2016
Ibero American University
2016
Amgen (Switzerland)
2015
Allergan (United States)
2011-2013
University of Colorado Anschutz Medical Campus
2011
Our objective was to characterize patterns of preventive medication use in persons with episodic migraine (EM) and chronic (CM).Several classes medications are used both on- off-label for the prevention migraine, including β-blockers (eg, propranolol, timolol), tricyclic antidepressants amitriptyline), anti-epileptic drugs topiramate, valproic acid), neurotoxins onabotulinumtoxinA).Preventive reasons discontinuation were collected an international, Web-based, cross-sectional survey adults...
Objective.— To provide evidence for the reliability and validity of Migraine‐Specific Quality Life Questionnaire Version 2.1 (MSQ) use in chronic migraine (CM) adults. Background.— MSQ is one most frequently utilized disease‐specific tools assessing impact on health‐related quality life (HRQL). However, its are based studies episodic (EM) populations. Additional patients with CM needed. Methods.— Cross‐sectional data were collected via web‐based survey 9 countries/regions. Participants...
The Migraine-Specific Quality of Life Questionnaire version 2.1 (MSQ) has been shown to have good psychometric performance in measuring headache impact migraine patients, but its properties specifically chronic (CM) patients are unknown. objective this study was evaluate the MSQ a group CM undergoing prophylactic treatment. Measurement were examined using two international, multicenter, randomized clinical trials evaluating onabotulinumtoxinA as prophylaxis (N = 1,376). Confirmatory factor...
BackgroundFirst-line (1L) and second-line (2L) therapies for advanced/metastatic gastric cancer (GC) gastroesophageal junction (GEJC) have modest efficacy, therapeutic options in subsequent lines are limited as disease progresses. We assessed real-world treatment patterns outcomes GC/GEJC.Patients MethodsAdult patients diagnosed with GC/GEJC between January 1, 2011 April 30, 2018 were identified using the Flatiron Health database. Median overall survival (OS) from start of each line therapy...
e23271 Background: BTKis are the standard of care for CLL/SLL in first-line (1L) and relapsed/refractory (R/R) settings. The next-generation BTKi zanubrutinib (zanu) demonstrated superiority over first-generation ibrutinib (ibr) treating R/R CLL, while second-generation acalabrutinib (acala) only showed noninferiority to ibr. We previously reported that 138 patients (pts) treated with zanu were more likely remain on treatment less require subsequent (tx) compared those acala 1L CLL community...
e23265 Background: Despite higher selectivity of the second-generation Bruton tyrosine kinase inhibitor (BTKi) acalabrutinib (acala) compared with first-generation BTKi ibrutinib (ibr), a notable fraction clinical trial patients treated acala discontinued treatment due to adverse events. The next-generation BTKi, zanubrutinib (zanu), was designed maximize efficacy and tolerability in by minimizing off-target binding. study objective evaluate characteristics, duration, reasons for...
e23270 Background: MCL is a rare and aggressive type of non-Hodgkin lymphoma. The next-generation BTKi, zanubrutinib (zanu), was developed to maximize efficacy tolerability in patients by minimizing off-target binding. FDA has approved acalabrutinib (acala), as single agent combination with bendamustine rituximab, zanu for treating relapsed/refractory MCL. first-generation ibrutinib (ibr), voluntarily withdrawn April 2023. Here, we evaluate the characteristics, treatment duration, reasons...
e23264 Background: Next-generation BTKi monotherapy is a preferred first-line (1L) treatment (tx) option, as categorized by the NCCN guidelines, for patients (pts) with CLL. In phase 3 randomized trials among pts relapsed or refractory CLL, zanubrutinib (zanu) demonstrated superior efficacy vs ibrutinib (ibr), while acalabrutinib (acala) only showed noninferiority to ibr. absence of head-to-head trial comparison, we evaluated real-world (rw) clinical outcomes in 1L CLL large US population....
e23263 Background: Newer BTK inhibitors zanubrutinib (ZANU) and acalabrutinib (ACA) are preferred over first-generation ibrutinib for chronic lymphocytic leukemia (CLL) treatment due to better toxicity profiles shown in randomized controlled trials. However, real-world (RW) evidence outcomes of ZANU ACA remains limited. Comparing diverse RW populations can provide critical insights inform clinical practice. Methods: This multi-center, RW, retrospective case-controlled study included adult...
e13741 Background: The NCCN guidelines for first-line (1L) regimens in CLL have evolved over the past decade, shifting from ibrutinib (ibr) and chemoimmunotherapy (CIT) to second-generation BTK inhibitor venetoclax combinations. We evaluated real-world use of preferred 1L treatment (tx) since 2016 patients (pts) routine care identify differences prescribing based on race/ethnicity practice type. Methods: This retrospective observational study utilized US nationwide Flatiron Health electronic...
The objective of this study is to estimate the cost-effectiveness KTE-X19 versus standard care (SoC) in treatment relapsed/refractory (R/R) mantle cell lymphoma (MCL) patients from a US healthcare perspective.A three-state partitioned-survival model (pre-progression, post-progression, and death) with cycle length 1 month was used extrapolate progression-free overall survival (OS) over lifetime horizon. Due long tail OS curve, modeled applying mixture-cure methodology, using assumption that...
Abstract Clinical guidelines recommend concurrent treatment of anemia in end‐stage renal disease with erythropoiesis‐stimulating agents ( ESA s) and iron. However, there are mixed data about optimal iron supplementation. To help address this gap, the relationship between markers hemoglobin Hb ) response to (Epoetin alfa) dose was examined. Electronic medical records 1902 US chronic hemodialysis patients were analyzed over a 12‐month period J une 2009 2010. The analysis included who had at...
Abstract Background There are few third-line or later (3L+) treatment options for advanced/metastatic (adv/met) gastric cancer/gastroesophageal junction cancers (GC/GEJC). 3L+ Nivolumab demonstrated encouraging results in Asian patients the ATTRACTION-2 study compared with placebo (12-month survival, 26% vs 11%), and Western single-arm CheckMate 032 44%). This analysis aimed to establish comparator cohorts of US receiving routine care real-world (RW) clinical practice. Methods A 2-step...
In this analysis, we compared costs and explored the cost-effectiveness of subsequent-line treatment with cetuximab or panitumumab in patients wild-type KRAS (exon 2) metastatic colorectal cancer (mCRC) after previous chemotherapy failure. Data were used from ASPECCT (A Study Panitumumab Efficacy Safety Compared to Cetuximab Patients With Wild-Type Metastatic Colorectal Cancer), a Phase III, head-to-head randomized noninferiority study comparing efficacy safety population.A decision-analytic...
Objective:To compare the costs of first-line treatment with panitumumab + FOLFOX in comparison to cetuximab FOLFIRI among patients wild-type (WT) RAS metastatic colorectal cancer (mCRC) US.Methods:A cost-minimization model was developed assuming similar efficacy between both regimens. The estimated associated drug acquisition, administration frequency (every 2 weeks for panitumumab, weekly cetuximab), and incidence infusion reactions. Average anti-EGFR doses were calculated from ASPECCT...
The assessment of real-world functional outcomes in clinical trials for medications targeting negative symptoms and cognitive impairment is extremely important. We tested the psychometric properties Daily Activity Report (DAR), a novel productive daily activity. administered DAR additional assessments outcome, capacity, cognition symptomatology to 50 individuals with schizophrenia at 2 time points, 1 month apart 25 healthy controls. records person’s activity 7 consecutive days based upon...
Panitumumab plus infusional 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) significantly improved overall survival versus FOLFOX4 alone in patients with previously untreated wild-type RAS metastatic colorectal cancer (mCRC). We applied a quality-adjusted time without symptoms of disease or toxicity (Q-TWiST) analysis to provide an integrated measure clinical benefit, the objective comparing between two arms. acknowledge that there are limitations associated Q-TWIST methodology for...
537 Background: The pivotal phase III PRIME trial demonstrated that, compared with FOLFOX alone, panitumumab plus prolongs overall survival and progression-free in patients RASWT mCRC without having a detrimental effect on quality of life. objective this analysis was to use the quality-adjusted time symptoms disease or toxicity treatment (Q-TWiST) method compare between arms PRIME. Methods: Patients from each arm were included analysis, area under curve (AUSC) estimated using nonparametric...
3543 Background: The pivotal phase III PRIME trial demonstrated that, compared with FOLFOX alone, panitumumab plus prolongs overall survival (OS) and progression-free (PFS) in patients RAS WT mCRC without having a detrimental effect on quality of life. objective this analysis was to use the quality-adjusted time symptoms disease or toxicity treatment (Q-TWiST) method compare between arms PRIME. Methods: Patients from each arm were included analysis, area under curve (AUSC) estimated using...
e19020 Background: BTKi therapies are standard of care for CLL/SLL, with acalabrutinib (acala) and zanubrutinib (zanu) having improved safety profiles vs ibrutinib (ibru). This study assessed real-world clinical characteristics, treatment patterns, adverse events (AEs) among BTKi-treated patients CLL/SLL. Methods: is a retrospective observational study, updated 5 months additional data from previous analysis. Adults in the US community oncology setting initiated between Jan 1, 2020, Jul 31,...